What's Happening?
Insulet has unveiled plans for new diabetes devices, including a fully automated insulin delivery system for individuals with Type 2 diabetes. The company is set to debut its Omnipod 6 device in 2027 and aims to launch a fully closed-loop system by 2028. This new system will not require users to input meals or count carbohydrates, making it more accessible and easier to manage. Insulet has completed enrollment in a safety and feasibility study, called Evolution 2, and plans to start a pivotal trial in 2026. The company is focusing on people with Type 2 diabetes who take basal and mealtime insulin, but also sees potential for those who only take basal insulin. Insulet's CEO, Ashley McEvoy, emphasized the company's commitment to improving customer
experience and removing barriers to access and affordability.
Why It's Important?
The development of a fully automated insulin delivery system by Insulet represents a significant advancement in diabetes management, particularly for individuals with Type 2 diabetes. This innovation could simplify the process of insulin administration, reducing the need for manual input and potentially improving adherence to treatment plans. By targeting Type 2 diabetes, Insulet is addressing a large and growing segment of the diabetes population, which could lead to increased market share and revenue growth. The company's focus on accessibility and affordability aligns with broader healthcare trends aimed at improving patient outcomes and reducing costs. Insulet's plans to expand its product offerings and enhance its current devices could solidify its leadership position in the automated insulin delivery market.
What's Next?
Insulet plans to start a pivotal trial for its fully closed-loop system in 2026, with a market launch expected in 2028. The company is also working on updates to its current Omnipod 5 system and plans to debut the Omnipod 6 device in 2027. Insulet will add a lower target range to the Omnipod 5 next year and connect the system with all major continuous glucose monitors. Additionally, Insulet is launching a new data platform for users and healthcare providers. These developments are expected to drive growth and expand Insulet's market presence, particularly in countries where its devices are not yet available.
